the following detailed description and examples are provided for the purpose of describing certain exemplary embodiments of the invention only , and are not intended to limit the scope of the invention in any way . the present invention provides preparations which contain chlorite ( e . g ., a metal chlorite such as sodium chlorite ) in combination with a small amount of hydrogen peroxide in neutral aqueous ( ph 6 . 0 - 8 . 8 , preferably ph 7 . 0 - 7 . 8 , and more preferably ph 7 . 0 - 7 . 4 ) solution . these preparations exhibit synergistic antimicrobial activity without generating chlorine dioxide during storage at room temperature , thereby rendering the stability of these solutions acceptable for pharmaceutical use . for example , an aqueous solution containing 400 ppm chlorite plus 100 ppm hydrogen peroxide remains stable beyond 18 months at room temperature , and is effective to reduce candida albicans activity by 1 . 0 log within six hours of challenge , even though the individual components of such solution are ineffective when applied separately at the same concentrations to reduce candida albicans activity . additionally , the hydrogen peroxide present within the chlorite / peroxide solutions of the present invention readily decomposes into molecular oxygen and water , upon contact with the peroxidase and catalase enzymes present in tissue and / or some body fluids . such in situ generation of molecular oxygen contributes to cell vitality and enhances wound healing . the chlorite / h 2 o 2 solutions of the present invention are sufficiently stable to be formulated in combination with polymeric lubricants ( non - ionic and / or anionic ; e . g ., hpmc , methocel , cmc , hyaluronic acid , etc .,) and / or in combination with block polymer based surfactants ( e . g ., pluronics ). for example , an aqueous chlorite / hydrogen peroxide system can be formulated together with methocel or hyaluronic acid as a lubricant and pluronics as a surfactant for contact lens disinfectant solution ( viscosity up to 50 cps at 25 degrees c .) in an ophthalmically acceptable tonicity ( e . g ., osmolality of at least about 200 mosmol / kg ) and a buffer to maintain the ph of the formulation within an acceptable physiological range . the formulation of the contact lens disinfection solution , artificial tear solution , and in - eye cleaner solution , contains chlorite preferably from about 0 . 005 to about 0 . 06 weight / volume percent and hydrogen peroxide preferably from about 0 . 0002 to about 0 . 05 weight / volume percent . again , the presence of hydrogen peroxide provides the beneficial oxygen molecule to the cornea upon contact with catalase in the tear . the chlorite / peroxide preparations of the present invention may be formulated in various ways , including liquid solutions , gels , ointments , creams , sprays , etc . set forth herebelow are a few examples of the types of specific formulations which may be prepared in accordance with this invention . the following formula 1 is a first preferred formulation of a liquid chlorite / peroxide solution of the present invention : formula 1 sodium chlorite 0 . 005 %- 0 . 10 % hydrogen peroxide 0 . 005 %- 0 . 05 % methocel a 0 . 05 %- 0 . 2 % boric acid 0 . 15 % sodium chloride 0 . 75 % pluronic f - 68 / f - 127 0 . 1 % hcl or naoh adjust ph 7 . 4 purified water q . s . to volume the following formula 2 is a second preferred formulation of a liquid chlorite / peroxide solution of the present invention : formula 2 sodium chlorite 0 . 05 % hydrogen peroxide 0 . 02 % carboxymethyl cellulose 0 . 01 % boric acid 0 . 15 % sodium chloride 0 . 75 % pluronic f - 68 / f - 127 0 . 1 % hcl or naoh adjust ph 7 . 3 purified water q . s . to volume the chlorite / peroxide solutions of the present invention , such as the solution of the above - shown preferred formulation , may be used for a variety of medical and non - medical applications including but not necessarily limited to a ) disinfection of articles and surfaces such as contact lenses , medical / dental instruments , counter tops , treatment tables , combs and brushes , etc . ; antisepsis of skin or body parts ( e . g ., a disinfectant hand wash , antiseptic facial scrub , etc .,) and b ) treatment or prophylaxis of dermal ( i . e ., skin or mucous membrane ) disorders such as wounds , burns , infections , ulcerations , cold sores , psoriasis , acne , and c ) deterrence or prevention of scar formation , and d ) treatment of ophthalmic disorders ( e . g ., infections or inflammations caused by bacterial keratitis ). as pointed out earlier , the chlorite / hydrogen peroxide system of the present invention is sufficiently stable to be formulated in a polymeric gel form or in a paste form . furthermore , such polymeric gel or paste formulation can contain polymers which delay or control the release of the chlorite / hydrogen peroxide ( e . g ., a sustained release delivery system ). such sustained release formulations provide outstanding benefits of increasing therapeutic index by maintaining the effective concentration of chlorite / h 2 o 2 for a prolonged time on the injured sites , by preventing the injured sites from external microbial contamination by forming a seal over the injured sites , and by providing oxygen molecule to the injured tissues . unlike the conventional ointment , the polymeric gel provides a dry , clean , and comfortable coating on the injured sites upon application . such gel formulations may contain polymeric drug delivery vehicles like hydroxypropyl methylcellulose ( hpmc ), methylcellulase ( methocel ), hydroxyethylcellulose ( hec ), hyaluronic acid , and carboxymethylcellulose ( cmc ), etc . the following formula 2 is a presently preferred formulation of a chlorite / peroxide gel of the present invention : formula 3 sodium chlorite 0 . 02 %- 0 . 10 % hydrogen peroxide 0 . 005 %- 0 . 05 % methocel a 2 . 0 % boric acid 0 . 15 % sodium chloride 0 . 75 % pluronic f - 68 / f - 127 0 . 1 % hcl or naoh adjust ph 7 . 4 purified water q . s . to volume any of the preparations of the present invention may be formulated for sustained release of the active components by forming liposomes of the preparing in accordance with well known liposomal forming techniques and / or by adding to the formulation a pharmaceutically acceptable and effective amount ( e . g ., typically 1 - 20 percent by weight ) of a sustained release component such as a polymer matrix or one or more of the following : the following formula 3 is a presently preferred formulation of a chlorite / peroxide contact lens disinfecting solution for use in cleaning contact lenses residing in or out of the eye . the formulation additionally functions as a tear product for lubrication in dry - eye subjects . formula 4 sodium chlorite 0 . 002 %- 0 . 20 % hydrogen peroxide 0 . 005 %- 0 . 05 % hyaluronic acid 0 . 001 %- 0 . 50 % boric acid 0 . 15 % sodium chloride 0 . 75 % pluroriic 127 0 . 05 %- 2 . 0 % hcl or naoh adjust ph to 7 . 4 purified water q . s . to volume as indicated earlier , the chlorite / peroxide preparation of the present invention , whether it be in the form of liquid solution , gel , ointment , cream , spray , etc ., is specifically composed to maintain chlorite such as sodium chlorite and hydrogen peroxide as active ingredients at a ph range of 6 . 0 - 8 . 8 without generating chlorine dioxide during storage at room temperature . by way of illustration , multiple experiments were conducted on the liquid sodium chlorite / hydrogen peroxide solution in accordance with formula 2 at different levels of ph within the specified range . however , it should be expressly stated herein that such experimentations should in no way be limited to liquid solution forms only , but are performed to illustrate the non - production of chlorine dioxide in the various forms of the present chlorite / peroxide preparation at different ph levels . the following experimentations were designed to demonstrate the stability of chlorite such as sodium chlorite and hydrogen peroxide antibacterial formulation at neutral , basic and acidic levels of ph . more specifically , the quantitative levels of sodium chlorite and the generation of chlorine dioxide were determined at the ph levels of 7 . 3 , 8 . 0 , 8 . 8 , 7 . 0 , 6 . 44 and 6 . 0 . 0 . 1 normal hydrochloric acid solution and 0 . 1 normal sodium hydroxide solution were applied to adjust the ph levels in the experimentations . sterile 0 . 9 % sodium chloride sterile solution was also applied . a placebo solution with the following formulation was further applied in a spectrophotometer ( e . g ., lambda 20 model uv — vis . spectrophotometer ) to find and measure the levels of sodium chlorite and the generation of chlorine dioxide at varying ph levels : placebo solution hydrogen peroxide 0 . 02 % carboxymethyl cellulose 0 . 01 % boric acid 0 . 15 % sodium chloride 0 . 75 % pluronic f - 68 / f - 127 0 . 1 % hcl or naoh adjust ph 7 . 3 purified water q . s . to volume experiment : fill the first cuvette with the placebo solution , wipe it clean , and place the cuvette in the standard beam path of the spectrophotometer . fill the second cuvette with the liquid sodium chlorite / hydrogen peroxide solution , wipe it clean and place the cuvette in the sample beam path of the spectrophotometer . scan the solutions from 200 nm to 400 nm and record the results . plot and printout the results , as illustrated in the graph shown in fig1 . result : the liquid solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at the ph level of 7 . 3 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at the ph level of 7 . 3 . hydrogen peroxide does not absorb in the 200 nm to 400 nm range . therefore , as seen in fig1 absorption peaks for hydrogen peroxide were not detected . sodium chlorite has an absorption maximum at 260 nm , while chlorine dioxide which is a degradation product of sodium chlorite has an absorption maximum at 355 nm - 358 nm . scanning the solutions that have a ph of 7 . 3 between the 200 nm and 400 nm will give a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . interpretation : the liquid sodium chlorite / hydrogen peroxide solution does show sodium chlorite peak at 260 nm , but does not show any chlorine dioxide peak at 355 nm - 358 nm . this clearly indicates that at ph level of 7 . 3 , the liquid sodium chlorite / hydrogen peroxide solution has only sodium chlorite , and does not contain any quantities of chlorine dioxide . this is a clear indication that sodium chlorite is stable at ph level of 7 . 3 , and the sodium chlorite is not breaking up and forming the chlorine dioxide . experiment : dispense 25 ml . of the placebo solution and 25 ml . of the liquid sodium chlorite / hydrogen peroxide solution into 2 clean containers . add 0 . 1 normal sodium hydroxide solution to each container so as to adjust the ph of both the placebo solution as well as the liquid solution to a ph level of 8 . 0 . fill one of the cuvette with the placebo solution , wipe it clean , and place the cuvette in the standard beam path of the spectrophotometer . fill the second cuvette with the liquid sodium chlorite / hydrogen peroxide solution , wipe it clean and place the cuvette in the sample beam path of the spectrophotometer . scan the solutions from 200 nm to 400 nm and record the results . plot and printout the results , as illustrated in the graph shown in fig2 . result : the liquid sodium chlorite / hydrogen peroxide solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at the ph level of 8 . 0 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at the ph level of 8 . 0 . as mentioned shortly above , hydrogen peroxide does not absorb in the 200 nm to 400 nm range . therefore , as seen in fig2 absorption peaks for hydrogen peroxide were not detected . as also mentioned above , sodium chlorite has an absorption maximum at 260 nm , while chlorine dioxide which is a degradation product of sodium chlorite has an absorption maximum at 355 nm - 358 nm . scanning the solutions that have a ph level of 8 . 0 between the 200 nm and 400 nm will give a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . interpretation : the liquid sodium chlorite / hydrogen peroxide solution does show sodium chlorite peak at 260 nm , but does not show any chlorine dioxide peak at 355 nm - 358 nm . this clearly indicates that at the ph level of 8 . 0 , the liquid sodium chlorite / hydrogen peroxide solution has only sodium chlorite , and does not contain any quantities of chlorine dioxide . this is a clear indication that sodium chlorite is stable at the ph level of 8 . 0 , and the chlorite is not breaking up and forming chlorine dioxide . dispense 25 ml . of the placebo solution and 25 ml . of the liquid sodium chlorite / hydrogen peroxide solution into 2 clean containers . add 0 . 1 normal sodium hydroxide solution to each container so as to adjust the ph of both the placebo solution as well as the liquid solution to a ph level of 8 . 8 . fill one of the cuvette with the placebo solution , wipe it clean , and place the cuvette in the standard beam path of the spectrophotometer . fill the second cuvette with the liquid sodium chlorite / hydrogen peroxide solution , wipe it clean and place the cuvette in the sample beam path of the spectrophotometer . scan the solutions from 200 nm to 400 nm and record the results . plot and printout the results , as illustrated in the graph shown in fig3 . result : the liquid sodium chlorite / hydrogen peroxide solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at the ph level of 8 . 8 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at the ph level of 8 . 8 . as already discussed , hydrogen peroxide does not absorb in the 200 nm to 400 nm range . therefore , as seen in fig3 absorption peaks for hydrogen peroxide were not detected . as also discussed , sodium chlorite has an absorption maximum at 260 nm , while chlorine dioxide which is a degradation product of sodium chlorite has an absorption maximum at 355 nm - 358 nm . scanning the solutions that have a ph level of 8 . 8 between the 200 nm and 400 nm will give a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . interpretation : the liquid sodium chlorite / hydrogen peroxide solution does show sodium chlorite peak at 260 nm , but does not show any chlorine dioxide peak at 355 nm - 358 nm . this clearly indicates that at the ph level of 8 . 8 , the liquid sodium chlorite / hydrogen peroxide solution has only sodium cholorite , and does not contain any quantities of chlorine dioxide . this is a clear indication that sodium chlorite is stable at the ph level of 8 . 8 , and the chlorite is not breaking up and forming chlorine dioxide . experiment : dispense 25 ml . of the placebo solution and 25 ml . of the liquid sodium chlorite / hydrogen peroxide solution into 2 clean containers . add 0 . 1 normal hydrochloric acid solution to each container so as to adjust the ph of both the placebo solution as well as the liquid solution to a ph level of 7 . 0 . fill one of the cuvette with the placebo solution , wipe it clean , and place the cuvette in the standard beam path of the spectrophotometer . fill the second cuvette with the liquid sodium chlorite / hydrogen peroxide solution , wipe it clean and place the cuvette in the sample beam path of the spectrophotometer . scan the solutions from 200 nm to 400 nm and record the results . plot and printout the results , as illustrated in the graph shown in fig4 . result : the liquid sodium chlorite / hydrogen peroxide solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at the ph level of 7 . 0 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at the ph level of 7 . 0 . hydrogen peroxide does not absorb in the 200 nm to 400 nm range . therefore , as seen in fig4 absorption peaks for hydrogen peroxide were not detected . sodium chlorite has an absorption maximum at 260 nm , while chlorine dioxide which is a degradation product of sodium chlorite has an absorption maximum at 355 nm - 358 nm . scanning the solutions that have a ph of 7 . 0 between the 200 nm and 400 nm will give a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . interpretation : the sodium chlorite / hydrogen peroxide solution does show sodium chlorite peak at 260 nm , but does not show any chlorine dioxide peak at 355 nm - 358 nm . this clearly indicates that at the ph level of 7 . 0 , the liquid solution has only sodium cholorite , and does not contain any quantities of chlorine dioxide . this is a clear indication that sodium chlorite is stable at ph of 7 . 0 , and the chlorite is not breaking up and forming chlorine dioxide . experiment : dispense 25 ml . of the placebo solution and 25 ml . of the liquid sodium chlorite / hydrogen peroxide solution into 2 clean containers . add 0 . 1 normal hydrochloric acid solution to each container so as to adjust the ph of both the placebo solution as well as the liquid solution to a ph level of 6 . 44 . fill one of the cuvette with the placebo solution , wipe it clean , and place the cuvette in the standard beam path of the spectrophotometer . fill the second cuvette with the liquid solution , wipe it clean and place the cuvette in the sample beam path of the spectrophotometer . scan the solutions from 200 nm to 400 nm and record the results . plot and printout the results , as illustrated in the graph shown in fig5 . result : the liquid sodium chlorite / hydrogen peroxide solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at the ph level of 6 . 44 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at ph = 6 . 44 . hydrogen peroxide does not absorb in the 200 nm to 400 nm range , and thus no absorption peaks for hydrogen peroxide were detected . sodium chlorite has an absorption maximum at 260 nm , while chlorine dioxide which is a degradation product of sodium chlorite has an absorption maximum at 355 nm - 358 nm . scanning the solutions that have a ph of 6 . 44 between the 200 nm and 400 nm will give a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . interpretation : the liquid sodium chlorite / hydrogen peroxide solution does show sodium chlorite peak at 260 nm , but does not show any chlorine dioxide peak at 355 nm - 358 nm . this clearly indicates that at ph of 6 . 44 , the liquid solution has only sodium cholorite , and does not contain any quantities of chlorine dioxide . this is a clear indication that sodium chlorite is stable at ph of 6 . 44 , and the chlorite is not breaking up and forming chlorine dioxide . experiment : dispense 25 ml . of the placebo solution and 25 ml . of the liquid sodium chlorite / hydrogen peroxide solution into 2 clean containers . add 0 . 1 normal hydrochloric acid solution to each container so as to adjust the ph of both the placebo solution as well as the liquid solution to a ph level of 6 . 0 . fill one of the cuvette with the placebo solution , wipe it clean , and place the cuvette in the standard beam path of the spectrophotometer . fill the second cuvette with the liquid sodium chlorite / hydrogen peroxide solution , wipe it clean and place the cuvette in the sample beam path of the spectrophotometer . scan the solutions from 200 nm to 400 nm and record the results . plot and printout the results , as illustrated in the graph shown in fig6 . result : the liquid sodium chlorite / hydrogen peroxide solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at the ph level of 6 . 0 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at the ph level of 6 . 0 . hydrogen peroxide does not absorb in the 200 nm to 400 nm range . therefore , as seen in fig6 absorption peaks for hydrogen peroxide were not detected . sodium chlorite has an absorption maximum at 260 nm , while chlorine dioxide which is a degradation product of sodium chlorite has an absorption maximum at 355 nm - 358 nm . scanning the solutions that have a ph of 6 . 0 between the 200 nm and 400 nm will give a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . interpretation : the sodium chlorite / hydrogen peroxide solution does show sodium chlorite peak at 260 nm , but does not show any chlorine dioxide peak at 355 nm - 358 nm . this clearly indicates that at ph level of 6 . 0 , the liquid solution has only sodium cholorite , and does not contain any quantities of chlorine dioxide . this is a clear indication that sodium chlorite is stable at ph of 6 . 0 , and the chlorite is not breaking up and forming chlorine dioxide . experiment : dispense 25 ml . of the placebo solution and 25 ml . of the liquid sodium chlorite / hydrogen peroxide solution into 2 clean containers . add 0 . 1 normal hydrochloric acid solution to each container so as to adjust the ph of both the placebo solution as well as the bactericidal solution to a ph of 1 . 5 . fill one of the cuvette with the placebo solution , wipe it clean , and place the cuvette in the standard beam path of the spectrophotometer . fill the second cuvette with the liquid solution , wipe it clean and place the cuvette in the sample beam path of the spectrophotometer . scan the solutions from 200 nm to 400 nm and record the results . plot and printout the results , as illustrated in the graph shown in fig7 . result : the liquid sodium chlorite / hydrogen peroxide solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at ph of 1 . 5 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at ph of 1 . 5 . as explained earlier , hydrogen peroxide does not absorb in the 200 nm to 400 nm range , and as such , no absorption peaks for hydrogen peroxide were detected . also explained earlier , sodium chlorite has an absorption maximum at 260 nm , while chlorine dioxide which is a degradation product of sodium chlorite has an absorption maximum at 355 nm - 358 nm . scanning the solutions that have a ph of 1 . 5 between the 200 nm and 400 nm will give a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . interpretation : the liquid sodium chlorite / hydrogen peroxide solution does not show sodium chlorite peak at 260 nm , but does show a large chlorine dioxide peak at 355 nm - 358 nm . this clearly indicates that at the ph level of 1 . 5 , the liquid sodium chlorite / hydrogen peroxide solution does not have any sodium chlorite . rather , it clearly shows that the sodium chlorite has been degraded and converted to chlorine dioxide . this is a clear indication that at ph of 1 . 5 , sodium chlorite is very unstable , and all chlorite that is present in the liquid solution is converted to chlorine dioxide . the liquid sodium chlorite / hydrogen peroxide solution contained sodium chlorite and hydrogen peroxide as active ingredients , as well as buffering and tonicity agents at the ph levels of 1 . 5 , 6 . 0 , 6 . 44 , 7 . 0 , 7 . 3 , 8 . 0 and 8 . 8 . the placebo solution contained hydrogen peroxide as active ingredient , as well as buffering and tonicity agents at the ph levels of 1 . 5 , 6 . 0 , 6 . 44 , 7 . 0 , 7 . 3 , 8 . 0 and 8 . 8 . hydrogen peroxide does not absorb in the 200 nm to 400 nm range . sodium chloride has an absorption maximum at 260 nm , while chlorine dioxide has an absorption maximum at 355 nm - 358 nm . scanning the solutions between the 200 nm and 400 nm gave a quantitative value for sodium chlorite as well as chlorine dioxide in the same scan . the liquid sodium chlorite / hydrogen peroxide solutions at the ph levels of 6 . 0 , 6 . 44 , 7 . 0 , 7 . 3 , 8 . 0 and 8 . 8 does show the presence of sodium chlorite peak at 260 nm , but does not show the presence of chlorine dioxide peak at 355 nm - 358 nm . in contrast , the liquid sodium chlorite / hydrogen peroxide solution at ph of 1 . 5 does not show the presence of sodium chlorite peak at 260 nm , but does show the presence of chlorine dioxide peak at 355 nm - 358 nm . the results clearly show that one can quantitatively determine the level of sodium chlorite as well as chlorine dioxide which is present in the liquid sodium chlorite / hydrogen peroxide solution at the ph levels of 1 . 5 , 6 . 0 , 6 . 44 , 7 . 0 , 7 . 3 , 8 . 0 and 8 . 8 . the results also show that the storage of the liquid sodium chlorite / hydrogen peroxide solution at about room temperature ( e . g ., in a white opaque bottle exposed to air at room temperature ) does not produce any chlorine dioxide as determined by the absence of any absorbance at 355 nm - 358 nm . in conclusion , the liquid sodium chlorite / hydrogen peroxide solution contains only sodium chlorite . it does not contain chlorine dioxide when it is manufactured , nor does the solution degrade to generate chlorine dioxide after storage at about room temperature at the ph levels of 6 . 0 , 6 . 44 , 7 . 0 , 7 . 3 , 8 . 0 and 8 . 8 . the liquid solution , however , degrades and generates chlorine dioxide upon the acidification of the solution to ph of 1 . 5 . this is clear evidence that the liquid sodium chlorite / hydrogen peroxide solution of the present invention has its bactericidal properties because of the sodium chlorite and hydrogen peroxide . this is very much unlike other prior art inventions that have as starting material as sodium chlorite , but the active bactericide is the chlorine dioxide , which is generated by the acidification of the sodium chlorite . the following are specific examples of therapeutic applications of the chlorite / peroxide preparations of the present invention . a human patient having psoriasis plaques present on both arms is treated as follows : twice daily application to plaques on the left arm only , of a chlorite / peroxide solution having the following formulation : sodium chlorite 0 . 06 % hydrogen peroxide 0 . 01 % hpmc 2 . 0 % boric acid 0 . 15 % hcl or naoh to adjust ph 7 . 4 purified water q . s . to volume twice daily application to plaques on the right arm only of a commercially available 0 . 1 % triamcinolone acetonide cream . the chlorite / peroxide treated psoriatic plaques on the right arm began to become less severe within 24 hours of beginning treatment and had substantially disappeared within three days of beginning treatment . however , the triamcinolone acetonide treated psoriatic plaques present on the left arm remained unchanged and inflamed during the two week treatment period . a human patient having psoriasis plaques present on both arms is treated for two weeks , as follows : twice daily application to plaques on the left arm only , of a chlorite / peroxide solution having the following formulation : sodium chlorite 0 . 06 % hydrogen peroxide 0 . 01 % hpmc 2 . 0 % boric acid 0 . 15 % hcl or naoh to adjust ph 7 . 4 purified water q . s . to volume / 100 % twice daily application to plaques on the right arm only of a commercially available 0 . 1 % triamcinolone acetonide cream . the chlorite / peroxide treated psoriatic plaques on the right arm began to become less severe within 24 hours of beginning treatment and had substantially disappeared within one week of beginning treatment . however , the triamcinolone acetonide treated psoriatic plaques present on the left arm remained unchanged and inflamed during the two week treatment period . beginning the day after the end of the initial two week treatment period , and continuing for a second two week treatment period , the patient was treated as follows : twice daily application to plaques on the left arm only of the same commercially available 0 . 1 % triamcinolone acetonide cream described hereabove in this example . twice daily application to plaques on the right arm only , of the same chlorite / peroxide sustained release gel described hereabove in this example . within 24 hours of commencing the second treatment period , the psoriatic lesions on the right arm began to subside . by day three and continuing through the end of the second two week treatment period , the psoriatic lesions on the right arm had substantially disappeared . a patient with painful , fluid - containing cold sores ( i . e ., chancre sores ) on his lips was treated twice daily by application to the lips of a chlorite / peroxide preparation prepared in accordance with formula 1 above . within 6 to 12 hours of the first application of the chlorite / peroxide preparation , the patient reported that the pain had subsided . within 24 hours of the first application of the chlorite / peroxide preparation , the fluid contained within the cold sores had substantially dissipated and the cold sores appeared dry . within six days of the first application of the chlorite / peroxide preparation the cold sores had substantially disappeared and the lips appeared normal , whereas cold sores of such severity typically require substantially longer than six days to completely disappear and heal . a patient with a venous ulcer on the right leg of 3 - 4 cm diameter which had been present for 9 - 12 months was treated by twice daily application to the ulcer of gauze soaked with a chlorite / peroxide liquid solution prepared in accordance with formula 1 above . within three days after commencement of treatment the ulcer appeared clean and dry . within 14 days of the commencement of treatment the ulcer began to decrease in size and healthy new tissue was observed about its periphery . at 35 days after commencement of treatment , the ulcer had completely healed , without scarring , and the area where the ulcer had been located was free of pain . a non - ambulatory , diabetic patient with decubitus ulcers on both legs and some toes , of 12 - 18 month duration , was treated by daily application of clean , sterile gauze to the ulcers and saturation of each gauze , three times each day , with a liquid chlorite / peroxide solution prepared in accordance with formula 1 above . within four to seven days of commencing the chlorite / hydrogen peroxide treatments the ulcers began to appear less inflamed , clean and dry . about seven to ten days after commencement of the chlorite / hydrogen peroxide treatment , granulation tissue began to form within the ulcers . within 12 to 14 days , re - epithelialization was observed to have begun within the ulcerated areas except for one toe ulcer which had been particularly severe and had permeated to the bone of the toe . within 30 to 45 days of the commencement of treatment , all of the ulcers except for the severe toe ulcer had completely closed and re - epithelialized , without irregular scar formation . also , at 30 to 45 days after the commencement of treatment , the toe ulcer had also become substantially smaller ( but was not completely closed ) and the patient was able to walk . the liquid and or gel formulations of the present invention , such as formulas 1 and 2 above , may also be applied topically to prevent scar formation due to wounds , burns , acne , infections , trauma , surgical incision , or any other scar - forming lesion or disorder . subjects with dry eye conditions have itchy and scratchy eyes . in extreme cases , the subjects have more serious problems that can interfere with health maintenance . subjects were treated with a preferred tear product of the following formulation : sodium chlorite 0 . 005 %- 0 . 02 % hydrogen peroxide 0 . 01 % methylcellulose a4m 0 . 075 % hyaluronic acid 0 . 10 %- 0 . 125 % boric acid 0 . 15 % sodium chloride , usp 0 . 75 % pluronic 127 0 . 10 % hcl or naoh adjust ph to 7 . 4 purified water q . s . to volume testing of dry eye subjects with rose bengal stain or fluorescein gives a good indication regarding the condition of the corneal epithelial health , while rose bengal staining provides a good indication of the number of dead epithelial cells on the cornea as well as conjunctiva . two subjects with dry eye condition were tested with rose bengal stain , and the quantitative staining to the cornea and conjunctiva was documented by photographs . the subjects started using the above preferred tear product at a dosage of two drops three times per day . at the end of two weeks , the two subjects were tested with rose bengal stain and the level of staining was quantitatively documented by photography . the results showed a 50 % to 70 % reduction in rose bengal staining , which clearly indicates that the preferred tear formulation was ameliorating the corneal and conjunctival cells from dying . in addition to an objective determination of the health of the epithelial cells , the two subjects were tested subjectively regarding the safety and efficacy of the preferred tear product . first of all , slit - lamp biomicroscopy of the subjects during the two - week treatment period did not show any redness , irritation , inflammation , or other signs of discomfort . second , the subjects indicated that the application of the tear product completely removed symptoms of redness , itching , scratching , pain , and dryness due to dry eye while providing lubrication that lasted for several hours . it is therefore evident that the tear product exhibits both safety and efficacy in the treatment of dry eye . as is further recognized in view of the foregoing antimicrobial activity of such compositions , the tear product will also have efficacy in enhancing wound healing within the eye such as after surgery where bacterial infections are to be avoided . in addition to treating dry eye condition with the above preferred tear product , the product was also tested in the treatment of conditions from allergic conjunctivitis . in particular , two subjects suffering from allergic conjunctivitis including itchy , scratchy eyes with constant tearing applied two drops of the product three times per day . this dosage resulted in the disappearance of the symptoms . the following formulation is a preferred disinfecting solution applicable to the cleaning of contact lenses by conventional soaking . sodium chlorite 0 . 05 % hydrogen peroxide 0 . 01 % methylcellulose a4m 0 . 075 % hyaluronic acid 0 . 05 %- 0 . 10 % boric acid 0 . 15 % pluronic 127 0 . 25 %- 0 . 50 % sodium chloride usp 0 . 75 % hcl or naoh adjust ph to 7 . 4 purified water q . s . to volume six subjects using soft hydrophilic contact lenses soaked the lenses in the above disinfecting solution and then placed the lenses directly into the eyes . soaking was performed nightly or on an as - needed basis . all six subjects reported that the lenses felt very comfortable , and that no adverse effects ( e . g ., burning , stinging , redness , pain ) were experienced . additionally , the solution extended the comfort and clean condition of the lenses for several weeks beyond such extension experienced with other commercially available disinfecting solutions . the disinfecting solution can be used with soft hydrophilic lenses of varying water content ( e . g ., 38 % to 75 %), as well as with silicone acrylate rigid gas permeable lenses . cycling studies of soft lenses soaked daily in the solution for 30 days showed no damage or change in the physical and chemical characteristics of the lenses . eye comfort , as earlier noted , is achieved through non - binding and non - accumulating of preservative in soft or rigid gas permeable lenses , while such binding and accumulation can be found in certain currently commercially available formulations to cause irritation and discomfort . the following formulation is a preferred disinfecting in - eye solution applicable to the cleaning of contact lenses while they are being worn by introducing the solution into the eye : sodium chlorite 0 . 02 % hydrogen peroxide 0 . 01 % methylcellulose a4m 0 . 075 % hyaluronic acid 0 . 075 %- 0 . 10 % boric acid 0 . 15 % sodium chloride usp 0 . 75 % pluronic 127 0 . 75 % hcl or naoh adjust ph to 7 . 4 purified water q . s . to volume four subjects applied two drops of the above in - eye solution three times per day for 30 days to contact lenses while being worn . examinations of all of the subjects showed no irritation , burning , stinging , or adverse effects of any kind . these subjects further reported that the solution felt soothing and lubricating . two subjects were involved in a comparative study where , first of all , they wore acuvue disposable lenses continuously for two weeks with occasional removal and cleaning with commercially available cleaning solutions followed with a saline rinse . after 14 days , the lenses became very gritty and uncomfortable , and were discarded . second , the two subjects started with new acuvue lenses and practiced daily application of the present in - eye solution three times per day without removing or touching the lenses . these subjects were able to wear the lenses for three to four weeks before replacement . additionally , the inconvenience of cleaning the lenses outside the eye was completely eliminated , as was the risk of lens loss , tearing , or contamination . it is therefore evident that the present in - eye cleaning solution provides cleansing efficacy as well as convenience . tables i and ii compare the antimicrobial effects of ( a ) 400 ppm sodium chlorite alone ; ( b ) 200 ppm hydrogen peroxide alone ; and ( c ) 400 ppm sodium chlorite and 200 ppm hydrogen peroxide in combination against antibiotic - resistant strains of staphylococcus haemolyticus ( table i ) and pseudomonas aeruginosa ( table ii ) both isolated from human infected eyes . tables i and ii summarize the antimicrobial effects observed at time points one and two hours after introduction of the test solutions . table i ( staphylococcus haemolyticus : initial inoculum = 1 . 01 × 10 7 : log 7 . 03 ) log reduction log reduction time naclo 2 alone h 2 o 2 alone naclo 2 & amp ; h 2 o 2 ( hours ) ( 400 ppm ) ( 200 ppm ) ( 400 ppm & amp ; 200 ppm ) 1 0 . 11 0 . 20 0 . 69 2 1 . 01 0 . 23 2 . 43 [ 0199 ] table ii ( pseudomonas aeruginosa : initial inoculum = 2 . 22 × 10 6 : log 6 . 35 ) log reduction log reduction time naclo 2 alone h 2 o 2 alone naclo 2 & amp ; h 2 o 2 ( hours ) ( 400 ppm ) ( 200 ppm ) ( 400 ppm & amp ; 200 ppm ) 1 0 . 351 0 . 01 0 . 04 2 1 . 35 0 . 54 6 . 35 in the experiment summarized in table i , sodium chlorite alone caused a log reduction in staphylococcus haemolyticus bacteria of 0 . 11 at 1 hour and 1 . 01 at 2 hours . hydrogen peroxide alone caused a log reduction in staphylococcus haemolyticus bacteria of 0 . 20 at 1 hour and 0 . 23 at 2 hours and the combination of sodium chlorite and hydrogen peroxide caused a log reduction in staphylococcus haemolyticus bacteria of 0 . 69 at 1 hour and 2 . 43 at 2 hours . thus , in this experiment , the antimicrobial effect of the sodium chlorite - hydrogen peroxide combination was significantly greater than the sums of the effects of the sodium chlorite and hydrogen peroxide alone , at least at the 2 hour time point . accordingly , it is concluded that the sodium chlorite - hydrogen peroxide combination exhibited a supra - additive effect against the strain of staphylococcus haemolyticus used in this experiment . in the experiment summarized in table ii , sodium chlorite along caused a log reduction in pseudomonas aeruginosa bacteria of 0 . 35 at 1 hour and 1 . 35 at 2 hours . hydrogen peroxide alone caused a log reduction in pseudomonas aeruginosa bacteria of 0 . 01 at 1 hour and 0 . 54 at 2 hours and the combination of sodium chlorite and hydrogen peroxide caused a log reduction in pseudomonas aeruginosa bacteria 0 . 04 at 1 hour and 6 . 35 at 2 hours . thus , in this experiment , the antimicrobial effect of the sodium chlorite - hydrogen peroxide combination was significantly greater than the sums of the effects of the sodium chlorite and hydrogen peroxide alone , at least in the 2 hour time point . accordingly , it is concluded that the sodium chlorite - hydrogen peroxide combination exhibited a supra - additive effect against the strain of pseudomonas aeruginosa used in this experiment . [ 0203 ] s . haemolyticus keratitus was induced in respective right eyes of 12 rabbits by dropping broth containing 50 , 000 cfu / ml of s . haemolyticus onto abraded corneas of these eyes . after 24 hours , all corneas were likewise infected , and the rabbits were divided randomly into three groups . the rabbits ( five ) of group i then were treated with the chlorite - hydrogen peroxide formulation defined above as cleaning while wearing contact lenses ( here termed “ bactericide ”); the rabbits ( five ) of group ii were treated with commercially available 0 . 3 % ofloxacin antibiotic ophthalmic solution ; and the rabbits ( two ) of group iii were untreated to serve as a control . at 24 and 48 hours post infection , the rabbits underwent visual eye examination , photographic documentation and biomicroscopy . after 24 hours of treatment , three animals each from groups i and ii and one animal from group iii were sacrificed . the eyes were enucleated and an 8 mm disc of cornea was homogenized and plated onto growth media for microbial isolation and quantification . after 48 hours of treatment , the same procedure was followed for the remaining animals . tables iii , iv and v summarize the results of this experimentation . as is there apparent , the bactericide of the present invention exhibited superior overall results as compared to the competing commercially available regimens . the results therefore confirm that the clinical efficacy of the bactericide is better than the antibiotic treatment . in addition to having excellent bactericidal properties , it is demonstrated that bactericide superiority is probably attributable to inactivation of bacterial proteolytic enzymes ( thus decreasing bacterial virulence ) and inactivation of bacterial toxins responsible for inflammation and hyperemia . table iii in - vivo antimicrobial efficacy in infectious s . haemolyticus keratitis in rabbits post group iii treatment group i group ii untreated time bactericide 0 . 3 % ofloxacin control 24 hours i ) 0 cfu i ) 23 , 000 cfu 39 , 000 cfu ii ) 18 , 000 cfu ii ) 5 , 000 cfu iii ) 0 cfu iii ) 11 , 000 cfu average 6 , 000 cfu 13 , 000 cfu 39 , 000 cfu 48 hours i ) 0 cfu i ) 5 , 000 cfu 231 , 000 cfu ii ) 0 cfu ii ) 5 , 200 cfu average 0 cfu 5 , 100 cfu 231 , 000 cpu [ 0206 ] table iv in - vivo clinical efficacy in infectious s . haemolyticus keratitis in rabbits group i group ii group iii time bactericide 0 . 3 % ofloxacin untreated control 24 hours inflammation (+ 2 ) inflammation (+ 2 ) inflammation (+ 2 ) after hyperemia (+ 2 ) hyperemia (+ 2 ) hyperemia (+ 2 ) infection corneal edema corneal edema (+ 2 ) corneal edema (+ 2 ) (+ 2 ) 24 hours inflammation ( 0 ) inflammation (+ 2 ) inflammation (+ 3 ) after hyperemia ( 0 ) hyperemia (+ 2 ) hyperemia (+ 3 ) treatment corneal edema ( 0 ) corneal edema (+ 2 ) corneal edema (+ 3 ) 48 hours inflammation ( 0 ) inflammation (+ 1 ) inflammation (+ 3 ) after hyperemia ( 0 ) hyperemia (+ 1 ) hyperemia (+ 3 ) treatment corneal edema ( 0 ) corneal edema (+ 1 ) corneal edema (+ 3 ) [ 0207 ] table v in - vitro inhibition of proteolytic enzyme activity inhibition f proteolytic enzyme activity of trypsin and porcine pancreatic elastase concentration of % inhibition of enzyme bactericide enzyme activity elastase ( porcine ) 0 . 18 ppm 46 % trypsin 0 . 12 ppm 28 % it will be appreciated by those skilled in the art , that the invention has been described hereabove with reference to certain examples and specific embodiments . however , these are not the only examples and embodiments in which the invention may be practiced . indeed , various modifications may be made to the above - described examples and embodiments without departing from the intended spirit and scope of the present invention , and it is intended that all such modifications be included within the scope of the following claims .
an anti - microbial composition for providing a therapeutic application onto a living being . the composition includes from about 0 . 001 wt . % to about 0 . 20 wt . % chlorite compound and from about 0 . 001 wt . % to about 0 . 05 wt . % peroxy compound . the anti - microbial composition of the present invention is composed to remain intact without being degraded to generate chlorine dioxide during storage at about a room temperature . the anti - microbial composition of the present invention is at a ph range between about 6 . 0 and about 8 . 8 .